According to WHO, the number of people living with diabetes has increased from 200 to 830 million in the past thirty-five years (since 1990). In 2020, more than a million people became blind due to diabetic retinopathy (DR), and almost 3.28 million suffered from moderate to severe visual impairment (MSI). DR is recognized as one of the most common causes of blindness and visual impairment among the working-age population worldwide. At the same time, early detection and treatment of MVI can reduce the risk of severe vision loss by approximately 90 percent. The scientific novelty of the article is that it substantiates the need for a combination of anti-VEGF, glucocorticosteroids, laser therapy and systemic treatment, taking into account the pathogenesis features of a particular patient. Particular attention is paid to the development of prolonged forms of anti-VEGF delivery, including implants - a direction that has strategic importance in reducing the frequency of injections. The article emphasizes the relationship between molecular, inflammatory, hemodynamic and neurovascular mechanisms in the development of diabetic retinopathy.
Laura Khachatrain (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: